Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Read more at MarketWatch
-
Alphabet shares fall more than 7% on revenue miss, AI investment boost
Alphabet shares dropped more than 7% after the search giant fell short of Wall Street's fourth-quarter revenue expectations and announced big spending plansCNBC - 20h -
Incredibly Expensive Video Games Are Not Necessary And Contribute To Job Losses, Exec Says
Saber Interactive founder Matthew Karch has shared some pointed words about the state of the AAA video game market. Speaking to reporter Stephen Totilo aboard a private jet that he paid $23 ...GameSpot - 20h -
Apple shares rise 3% as boost in services revenue overshadows iPhone miss
Although Apple's overall sales rose during the quarter, the company's closely watched iPhone sales actually declined slightly on a year-over-year basis.CNBC - 6d -
SoFi’s stock sinks as a downbeat outlook negates a big revenue beat
SoFi’s stock sinks as a mixed outlook overshadowed strong Q4 results that included the biggest revenue beat in about three years.MarketWatch - Jan. 27 -
World's biggest chipmaker TSMC posts record 2024 revenue as AI boost continues
TSMC manufacturers semiconductors for some of the world's biggest companies from Apple to Nvidia.CNBC - Jan. 10 -
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.CNBC - Jan. 9 -
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment costs about $1,000 a month without insurance.MarketWatch - Jan. 9 -
Eli Lilly's lead in the obesity race has grown. Its recent stock performance says otherwise
Eli Lilly has been one of the worst-performing Club stocks over the past six months.CNBC - Jan. 8
More from MarketWatch
-
Ralph Lauren credits stronger-than-expected holiday season as stock rises on earnings boost
Looking ahead, the company said it does not expect to see an impact from U.S. tariffs on goods from China, Mexico and China.MarketWatch - 10m -
Ralph Lauren credits stronger-than-expected holiday season as stock rises on earnings boost
Looking ahead, the company said it does not expect to see an impact from U.S. tariffs on goods from China, Mexico and China.MarketWatch - 10m -
Cannabis stocks extend gains on RFK Jr. committee vote, Senate banking comments
Robert F. Kennedy Jr., seen as pro-cannabis, is heading toward expected approval as Health and Human Services secretary, while cannabis-industry banking woes were aired during a committee hearing ...MarketWatch - 29m -
Yum Brands becomes latest fast-food company to lean in to AI, and its stock gains
Yum is ramping up its artificial-intelligence efforts, which include AI-driven marketing to enable “hyperpersonalized messaging and experiences.”MarketWatch - 40m -
Here’s what is pushing Ford’s stock to its worst showing in 4 years
Ford Motor Co. shares extended their slide Thursday as the carmaker’s soft outlook for this year spooked Wall Street.MarketWatch - 40m
More in Business
-
L’Oreal sales slightly miss in fourth quarter as China weakness persists
French cosmetics giant L'Oreal on Thursday reported a lower than expected increase in fourth-quarter sales amid continued weakness in the Chinese beauty market.CNBC - 3m -
Ralph Lauren credits stronger-than-expected holiday season as stock rises on earnings boost
Looking ahead, the company said it does not expect to see an impact from U.S. tariffs on goods from China, Mexico and China.MarketWatch - 10m -
Ralph Lauren credits stronger-than-expected holiday season as stock rises on earnings boost
Looking ahead, the company said it does not expect to see an impact from U.S. tariffs on goods from China, Mexico and China.MarketWatch - 10m -
Roblox plummets 14% on disappointing bookings, daily active users miss
Roblox shares plunged 14% after falling short of Wall Street's bookings and daily active user estimates.CNBC - 11m -
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Zepbound and Mounjaro have now underperformed expectations for two straight quarters.CNBC - 19m